Impact of the cancer risk intake system on patient-clinician discussions of tamoxifen, genetic counseling, and colonoscopy

Journal of General Internal Medicine

Volumn 20, Issue 4, 2005, Pages 360-365

  Skinner, Celette Sugg ^a   Rawl, Susan M ^b   Moser, Barry K ^a   Buchanan, Adam H ^a   Scott, Linda L ^b   Champion, Victoria L ^b   Schildkraut, Joellen M ^a   Parmigiani, Giovanni ^c   Clark, Shelly ^a   Lobach, David F ^a   Bastian, Lori A ^d  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b INDIANA UNIVERSITY SCHOOL OF NURSING   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d DURHAM VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TAMOXIFEN;

ARTICLE; CANCER; CANCER RISK; CLINICAL PRACTICE; COLONOSCOPY; COMPUTER PROGRAM; DOCTOR PATIENT RELATION; GENETIC COUNSELING; HEALTH CARE QUALITY; HEALTH SURVEY; HUMAN; MEDICAL EDUCATION; PRIMARY MEDICAL CARE; RISK MANAGEMENT; SELF REPORT; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; COLONIC NEOPLASMS; COLONOSCOPY; COMMUNICATION; COUNSELING; FEMALE; GENETIC COUNSELING; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; OVARIAN NEOPLASMS; PATIENT ACCEPTANCE OF HEALTH CARE; PATIENT EDUCATION; PHYSICIAN-PATIENT RELATIONS; PRIMARY HEALTH CARE; RISK ASSESSMENT; TAMOXIFEN;

EID: 18144390845     PISSN: 08848734     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1525-1497.2005.40115.x     Document Type: Article

References (46)

1. Myles J, Duffy S, Nixon R, et al. Initial results of a study into the effectiveness of breast cancer screening in a population identified to be at high risk. Revue de Epidemiologie et de Sante Publique. 2001;49:471-5.
2. Tilanus-Linthorst MM, Bartels CC, Obdeijn AI, Oudkerk M. Earlier detection of breast cancer by surveillance of women at familial risk. Eur J Cancer. 2000;36:514-9.
3. Burt RW. Colon cancer screening. Gastroenterology. 2000;119:837-53.
4. Lieberman D. Screening/early detection model for colorectal cancer. Why screen? Cancer. 1994;74:2023-7.
5. Brekelmans CT, Seynaeve C, Bartels CC, et al. Effectiveness of breast cancer surveillance in BRCA1/2 gene mutation carriers and women with high familial risk. J Clin Oncol. 2001;19:924-30.
6. Winawer S, Fletcher R, Rex D, et al. Colorectal cancer screening and surveillance: clinical guidelines and rationale - update based on new evidence. Gastroenterology. 2003;124:544-60.
7. Smith RA, Cokkinides V, Eyre HJ. American Cancer Society. American Cancer Society guidelines for the early detection of cancer. 2003. CA Cancer J Clin. 2003;53:27-43.
8. Fisher B, Costantino JP, Wickerham DL. et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90:1371-88.
9. Kinsinger LS, Harris R, Woolf SH, Sox HC, Lohr KN. Chemoprevention of breast cancer: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2002;137:59-69.
10. Freedman AN, Graubard BI, Rao SR, McCaskill-Stevens W, Ballard-Barbash R, Gail MH. Estimates of the number of US women who could benefit from tamoxifen for breast cancer chemoprevention. J Natl Cancer Inst. 2003;95:526-32.
11. Pichert G, Bolliger B, Buser K, Pagani O. Swiss Institute for Applied Cancer Research Network for Cancer Predisposition Testing and Counseling. Evidence-based management options for women at increased breast/ovarian cancer risk. Ann Oncol. 2003;14:9-19.
12. Gail MH, Costantino JP, Bryant J, et al. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst. 1999;91:1829-46.
13. Biesecker BB, Boehnke M, Calzone K, et al. Genetic counseling for families with inherited susceptibility to breast and ovarian cancer. JAMA. 1993;269:1970-4.
14. Morris KT, Johnson N, Krasikov N, Allen M, Dorsey P. Genetic counseling impacts decision for prophylactic surgery for patients perceived to be at high risk for breast cancer. Am J Surg. 2001;181:431-3.
15. Meiser B, Butow PN, Barratt AL, et al. Long-term outcomes of genetic counseling in women at increased risk of developing hereditary breast cancer. Patient Educ Couns. 2001;44:215-25.
16. Meiser B, Halliday JL. What is the impact of genetic counselling in women at increased risk of developing hereditary breast cancer? A meta-analytic review. Soc Sci Med. 2002;54:1463-70.
17. American Society of Clinical Oncology. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. J Clin Oncol. 2003;21:2397-406.
18. Collins FS. BRCA1 - lots of mutations, lots of dilemmas. N Engl J Med. 1996;334:186-8.
19. Worthen HG. Inherited cancer and the primary care physician. Barriers and strategies. Cancer. 1999;86:2583-8.
20. Friedman LC, Woodruff A, Lane M, Weinberg AD, Cooper HP, Webb JA. Breast cancer screening behaviors and intentions among asymptomatic women 50 years of age and older. Am J Prev Med. 1995;11:218-23.
21. Love RR, Brown RL, Davis JE, Baumann LJ, Fontana SA, Sanner LA. Frequency and determinants of screening for breast cancer in primary care group practice. Arch Intern Med. 1993;153:2113-7.
22. Vernon SW. Participation in colorectal cancer screening: a review. J Natl Cancer Inst. 1997;89:1406-22.
23. Kreuter MW, Chheda SG, Bull FC. How does physician advice influence patient behavior? Evidence for a priming effect. Arch Fam Med. 2000;9:426-33.
24. Sweet KM, Bradley TL, Westman JA. Identification and referral of families at high risk for cancer susceptibility. J Clin Oncol. 2002;20:528-37.
25. Westman J, Hampel H, Bradley T. Efficacy of a touchscreen computer based family cancer history questionnaire and subsequent cancer risk assessment. J Med Genet. 2000;37:354-60.
26. Ryan EL, Skinner CS. Risk beliefs and interest in counseling: focus-group interviews among first-degree relatives of breast cancer patients. J Cancer Educ. 1999;14:99-103.
27. Todora HM, Skinner CS, Gidday L, Ivanovich JL, Rawl S, Whelan AJ. Perceptions of genetic risk assessment and education among first degree relatives of colorectal cancer patients and implications for physicians. Fam Pract. 2001;18:367-72.
28. Harris MA, Byles JE. A survey of screening compliance among first degree relatives of people with colon cancer in New South Wales. J Med Screen. 1997;4:29-34.
29. Richardson JL, Danley K, Mondrus GT, Deapen D, Mack T. Adherence to screening examinations for colorectal cancer after diagnosis in a first-degree relative. Prev Med. 1995;24:166-70.
30. Hampel H, Sweet K, Westman JA, Offit K, Eng C. Referral for cancer genetics consultation: a review and compilation of risk assessment criteria. J Med Genet. 2004;41:81-91.
31. Berry DA, Iversen ES Jr, Gudbjartsson DF, et al. BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. J Clin Oncol. 2002;20:2701-12.
32. Parmigiani G, Berry D, Aguilar O. Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet. 1998;62:145-58.
33. Berry D, Parmigiani G, Sanchez J, Schildkraut J, Winer E. Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history. J Natl Cancer Inst. 1997;89:227-38.
34. Stokes M, David C, Koch G. Categorical Data Analysis Using the SAS System. 2nd ed. Cary, NC: SAS Institute Inc.; 2000:10-41.
35. Bastian LA, Lipkus IM, Kuchibhatla MN, et al. Women's interest in chemoprevention for breast cancer. Arch Intern Med. 2001;161:1639-44.
36. Haas JS, Kaplan C, Gregorich S, Perez-Stable E, Des Jarlais G. Do physicians tailor their recommendations for breast cancer risk reduction based on patient's risk? J Gen Intern Med. 2004;19:302-9.
37. Campbell H, Holloway S, Cetnarskyj R, et al. Referrals of women with a family history of breast cancer from primary care to cancer genetics services in south-east Scotland. Br J Cancer. 2003;89:1650-6.
38. Watson E, Austoker J, Lucassen A. A study of GP referrals to a family cancer clinic for breast/ovarian cancer. Fam Pract. 2001;18:131-4.
39. Fry A, Campbell H, Gudmunsdottir H, et al. GPs' views on their role in cancer genetics services and current practice. Fam Pract. 1999;16:468-74.
40. Klabunde CN, Frame PS, Meadow A, Jones E, Nadel M, Vernon SW. A national survey of primary care physicians' colorectal cancer screening recommendations and practices. Prev Med. 2003;36:352-62.
41. Patel P, Forjuoh S, Avots-Avotins A, Patel T. Identifying opportunities for improved colorectal cancer screening in primary care. Prev Med. 2004;39:239-46.
42. Ward J, Sanson-Fisher R. Does a 3-day workshop for family medicine trainees improve preventive care? A randomized control trial. Prev Med. 1996;25:741-7.
43. Daskalakis C, Goldberg RJ, Ockene JK, Kalan K, Hosmer DW Jr, Pbert L. Comparison of patients' and their resident physicians' responses regarding smoking-cessation interventions. Acad Med. 1993;68:168-70.
44. Nicholson JM, Hennrikus DJ, Lando HA, McCarty MC, Vessey J. Patient recall versus physician documentation in report of smoking cessation counselling performed in the inpatient setting. Tob Control. 2000;9:382-8.
45. Roter DL, Russell NK. Validity of physician self-report in tracking patient education objectives. Health Educ Q. 1994;21:27-38.
46. Pbert L, Adams A, Quirk M, Hebert JR, Ockene JK, Luippold RS. The patient exit interview as an assessment of physician-delivered smoking intervention: a validation study. Health Psychol. 1999;18: 183-8.